BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 27566041)

  • 1. From bench to bedside: Clinical implications of KRAS status in patients with colorectal liver metastasis.
    Andreatos N; Ronnekleiv-Kelly S; Margonis GA; Sasaki K; Gani F; Amini N; Wilson A; Pawlik TM
    Surg Oncol; 2016 Sep; 25(3):332-8. PubMed ID: 27566041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
    Margonis GA; Kim Y; Sasaki K; Samaha M; Amini N; Pawlik TM
    Cancer; 2016 Sep; 122(17):2698-707. PubMed ID: 27244540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
    Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
    Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
    Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
    JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of KRAS Mutation on Long-Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases.
    Margonis GA; Spolverato G; Kim Y; Karagkounis G; Choti MA; Pawlik TM
    Ann Surg Oncol; 2015 Dec; 22(13):4158-65. PubMed ID: 26077912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.
    Margonis GA; Kim Y; Spolverato G; Ejaz A; Gupta R; Cosgrove D; Anders R; Karagkounis G; Choti MA; Pawlik TM
    JAMA Surg; 2015 Aug; 150(8):722-9. PubMed ID: 26038887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis.
    Tosi F; Magni E; Amatu A; Mauri G; Bencardino K; Truini M; Veronese S; De Carlis L; Ferrari G; Nichelatti M; Sartore-Bianchi A; Siena S
    Clin Colorectal Cancer; 2017 Sep; 16(3):e153-e163. PubMed ID: 28216246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis.
    Passiglia F; Bronte G; Bazan V; Galvano A; Vincenzi B; Russo A
    Crit Rev Oncol Hematol; 2016 Mar; 99():150-7. PubMed ID: 26775732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Role of BRAF Mutations in Colorectal Cancer Liver Metastases.
    Pikoulis E; Margonis GA; Andreatos N; Sasaki K; Angelou A; Polychronidis G; Pikouli A; Riza E; Pawlik TM; Antoniou E
    Anticancer Res; 2016 Sep; 36(9):4805-11. PubMed ID: 27630332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resection of Colorectal Liver Metastasis: Prognostic Impact of Tumor Burden vs KRAS Mutational Status.
    Tsilimigras DI; Hyer JM; Bagante F; Guglielmi A; Ruzzenente A; Alexandrescu S; Poultsides G; Sasaki K; Aucejo F; Pawlik TM
    J Am Coll Surg; 2021 Apr; 232(4):590-598. PubMed ID: 33383214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS Mutation Status Predicts Site-Specific Recurrence and Survival After Resection of Colorectal Liver Metastases Irrespective of Location of the Primary Lesion.
    Shindoh J; Nishioka Y; Yoshioka R; Sugawara T; Sakamoto Y; Hasegawa K; Hashimoto M; Kokudo N
    Ann Surg Oncol; 2016 Jun; 23(6):1890-6. PubMed ID: 26786089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant Hepatic Artery Infusion Chemotherapy is Associated With Improved Survival Regardless of KRAS Mutation Status in Patients With Resected Colorectal Liver Metastases: A Retrospective Analysis of 674 Patients.
    Gholami S; Kemeny NE; Boucher TM; Gönen M; Cercek A; Kingham TP; Balachandran V; Allen P; DeMatteo R; Drebin J; Jarnagin W; D'Angelica M
    Ann Surg; 2020 Aug; 272(2):352-356. PubMed ID: 32675549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases.
    Kemeny NE; Chou JF; Capanu M; Gewirtz AN; Cercek A; Kingham TP; Jarnagin WR; Fong YC; DeMatteo RP; Allen PJ; Shia J; Ang C; Vakiani E; D'Angelica MI
    Cancer; 2014 Dec; 120(24):3965-71. PubMed ID: 25155157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Implication of KRAS Status after Hepatectomy for Colorectal Liver Metastases Varies According to Primary Colorectal Tumor Location.
    Sasaki K; Margonis GA; Wilson A; Kim Y; Buettner S; Andreatos N; Gani F; Amini N; Spolverato G; Pawlik TM
    Ann Surg Oncol; 2016 Oct; 23(11):3736-3743. PubMed ID: 27352204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is Hepatectomy Justified for BRAF Mutant Colorectal Liver Metastases?: A Multi-institutional Analysis of 1497 Patients.
    Gagnière J; Dupré A; Gholami SS; Pezet D; Boerner T; Gönen M; Kingham TP; Allen PJ; Balachandran VP; De Matteo RP; Drebin JA; Yaeger R; Kemeny NE; Jarnagin WR; D'Angelica MI
    Ann Surg; 2020 Jan; 271(1):147-154. PubMed ID: 29995686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Demystifying BRAF Mutation Status in Colorectal Liver Metastases : A Multi-institutional, Collaborative Approach to 6 Open Clinical Questions.
    Margonis GA; Boerner T; Bachet JB; Buettner S; Moretto R; Andreatos N; Sartore-Bianchi A; Wang J; Kamphues C; Gagniere J; Lonardi S; Løes IM; Wagner D; Spallanzani A; Sasaki K; Burkhart R; Pietrantonio F; Pikoulis E; Pawlik TM; Truant S; Orlandi A; Pikouli A; Pella N; Beyer K; Poultsides G; Seeliger H; Aucejo FN; Kornprat P; Kaczirek K; Lønning PE; Kreis ME; Wolfgang CL; Weiss MJ; Cremolini C; Benoist S; D'Angelica M
    Ann Surg; 2023 Sep; 278(3):e540-e548. PubMed ID: 36453261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The interplay of KRAS mutational status with tumor laterality in non-metastatic colorectal cancer: An international, multi-institutional study in patients with known KRAS, BRAF, and MSI status.
    Kamphues C; Kadowaki S; Amini N; van den Berg I; Wang J; Andreatos N; Sakamoto Y; Ogura T; Kakuta M; Pikouli A; Geka D; Daitoku N; Theochari M; Buettner S; Akiyama T; Antoniou E; Pikoulis E; Theodoropoulos G; Imai K; Ijzermans JNM; Margonis GA; Akagi K; Kreis ME
    J Surg Oncol; 2021 Mar; 123(4):1005-1014. PubMed ID: 33368279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Not All Kirsten Rat Sarcoma Viral Oncogene Homolog Mutations Predict Poor Survival in Patients With Unresectable Colorectal Liver Metastasis.
    Lin Z; Liu Y; Cai S; Yang C; Zhou L; Li W
    Technol Cancer Res Treat; 2021; 20():15330338211039131. PubMed ID: 34669528
    [No Abstract]   [Full Text] [Related]  

  • 19. Differential effects of KRAS mutational status on long-term survival according to the timing of colorectal liver metastases.
    Sakai N; Furukawa K; Takayashiki T; Kuboki S; Takano S; Ohtsuka M
    BMC Cancer; 2021 Apr; 21(1):412. PubMed ID: 33858364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of BRAF mutations on clinical outcomes following liver surgery for colorectal liver metastases: An updated meta-analysis.
    Gau L; Ribeiro M; Pereira B; Poirot K; Dupré A; Pezet D; Gagnière J
    Eur J Surg Oncol; 2021 Nov; 47(11):2722-2733. PubMed ID: 34099355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.